Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial

Nat Med. 2024 Oct 16. doi: 10.1038/s41591-024-03348-1. Online ahead of print.
No abstract available

Publication types

  • Published Erratum